Atrial Flutter Versus Atrial Fibrillation in a General Population: Differences in Comorbidities Associated With Their Respective Onset

Ravi K. Mareedu, MD; Ihab B. Abdalrahman, MD; Kodlipet C. Dharmashankar, MD; Juan F. Granada, MD; Po-Huang Chyou, PhD; Param P. Sharma, MD; Peter N. Smith, MD; John J. Hayes, MD; Robert T. Greenlee, PhD and Humberto Vidaillet, MD

Corresponding Author:
Humberto Vidaillet, MD
Cardiovascular Electrophysiology
Department of Cardiology
Marshfield Clinic
1000 North Oak Avenue
Marshfield, WI 54449
Tel: 715-387-5080
Fax: 715-389-5757
E-mail address: vidaillet.humberto@marshfieldclinic.org

doi:10.3121/cmr.2009.851

Grant Support: Grant 1UL1RR025011, Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health

Received: February 4, 2009
Revised: September 25, 2009
Accepted: October 7, 2009

Copyright 2009 by Marshfield Clinic.
Abstract

Objective: Determine and compare the prevalence of known risk factors for cardiovascular disease among unselected individuals presenting with their first ever episode of atrial flutter (AFL) and atrial fibrillation (AF).

Study Design and Setting: We evaluated 11 pre-selected clinical variables including age, sex, smoking history and other potential cardiac risk factors. Using the resources of the Marshfield Epidemiologic Study Area, a population-based database, all newly diagnosed cases of either AFL or AF in the region during a 4-year period were identified.

Results: Among the 472 incident cases, 76 (16.1%) had AFL and 396 (83.9%) had AF. Compared to those with AF, subjects with AFL were more likely to have had a history of chronic obstructive pulmonary disease (25% vs. 12%, \( P = 0.006 \)), heart failure (28% vs. 17%, \( P = 0.05 \)), and smoking (49% vs. 37%, \( P = 0.06 \)). Hypertension, on the other hand, was more common among individuals with AF (63% vs. 47%, \( P = 0.01 \)).

Conclusion: This study represents the first report to evaluate potential differences in the conditions associated with the development of AFL versus AF. Research into the mechanisms of atrial arrhythmogenesis may lead to improved preventive and therapeutic interventions.

Keywords: Arrhythmias, Clinical electrophysiology, Drugs, Epidemiology
trial flutter (AFL) and atrial fibrillation (AF) are the two most common sustained cardiac arrhythmias encountered in clinical practice. Recent advances in our understanding of the distinct electrophysiologic mechanisms responsible for AFL and AF have led to specific anatomically-based curative procedures.¹,²

Unlike other common cardiovascular disorders such as atherosclerosis, heart failure, sudden death, etc. in which detailed knowledge about specific predisposing risk factors have resulted in effective preventive strategies and improved assessment of individuals at risk, the conditions responsible for AFL and AF, and the reasons why any given patient may develop one of these arrhythmias and not the other remain largely unknown.

Methods

Marshfield Epidemiologic Study Area (MESA)

MESA is a population-based cohort established in 1991 to support epidemiologic research within the context of integrated health care delivery.³ Such studies are possible in central Wisconsin because nearly all residents choose to receive their medical care from Marshfield Clinic (with its 40 regional centers) and St. Joseph’s Hospital. The central portion of MESA includes 14 ZIP codes in Marshfield and surrounding communities, and is home to more than 54,000 residents. In this region, Marshfield Clinic's electronic medical record systems have been shown to capture 97% of the people, more than 90% of outpatient visits, 99% of deaths, and 95% of hospital stays.⁴ Residents of MESA represent a well-defined, unselected population, reducing the referral bias often influencing other health care study populations. With daily updates about the health care status and population characteristics, MESA provides a unique opportunity to conduct
epidemiological association and frequency studies, and has supported a number of studies of cardiac arrhythmias and other cardiovascular conditions.\textsuperscript{4-9} This investigation was reviewed and approved by the Marshfield Clinic Institutional Review Board.

Electrocardiographic (ECG) Definitions

ECG definitions have been detailed earlier,\textsuperscript{7} and they are summarized below. Only patients satisfying ECG documentation of their first ever episode of either AFL or AF were enrolled. A cardiac electrophysiologist confirmed all ECG diagnoses. While the minimum duration of continuous ECG documentation of each of these arrhythmias required for study was 5 seconds, virtually all incidents lasted minutes to days. ECG criteria used for study entry was as follows:

- **AFL** was considered to be present if there were visible and highly regular “F” waves at a rate ≤350 beats per minute. Highly regular "F" waves were defined as those in which the cycle to cycle atrial variability was ≤10 msec. Atrial rate in AFL had to be >190 beats per minute among patients receiving classes IA, IC and/or class III anti-arrhythmic agents. In all others, the lowest acceptable atrial rate was 240 beats per minute.

- **AF** was defined by the presence of fibrillatory waves of variable size, shape and timing associated with an irregular ventricular response when atrioventricular response is intact.

Patient Selection Criteria

To identify potential incident cases of AFL or AF in MESA occurring from July 1, 1991 through June 30, 1995, we used Marshfield Clinic’s diagnostic database. Since 1979, this database has used the International Classification of Diseases 9th Revision (ICD-9) to track all diagnoses
recorded by Marshfield Clinic patients in the inpatient and outpatient setting. In addition to ICD 427.31 (AF) and 427.32 (AFL), we screened for potential cases using 7 additional diagnostic codes including 410 (acute myocardial infarction), 426.7 (Wolff-Parkinson-White syndrome), 427.0 (paroxysmal supraventricular tachycardia), 427.2 (paroxysmal tachycardia, unspecified), 427.81 (sinoatrial node dysfunction), 427.89 (other rhythm disorder, ectopic, nodal and wandering atrial pacemaker) and 427.9 (cardiac dysrhythmia, unspecified). While all potential cases were assessed for study entry, final inclusion required ECG confirmation by cardiac electrophysiologists. Given that the focus of this investigation was to evaluate the possible association of certain clinical variables with the initial onset of AFL or AF, subjects who in addition to their primary arrhythmia also had antecedent or concomitant AFL or AF, on detailed review of the medical records, were excluded. During the 220,000 person-years of observation, approximately 29,000 electrocardiograms and rhythm strips, 1100 Holter monitors and 500 ambulatory event recordings were obtained from MESA residents.

Clinical Variables and Data Collection

A written glossary defining all premorbid conditions under consideration was developed a priori. These included age, gender, heart failure, chronic pulmonary disease, systemic hypertension, previous stroke, myocardial infarction, rheumatic heart disease, smoking history, thyroid abnormality and diabetes mellitus. The full medical record of each incident case, including admission, discharge, inpatient and outpatient procedure, and clinical notes was abstracted by a trained study nurse to determine the presence of premorbid conditions prior to the diagnosis of the atrial arrhythmia. Quality assurance methods to ensure data integrity included re-abstraction of every 10th medical record, double data entry of a random sample of 10% of collected
information, as well as range and edit checks on all collected data. All predetermined quality assurance parameters were exceeded.

Statistical Analysis

Clinical variables in the analysis included age, sex, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), hypertension, previous stroke, myocardial infarction, rheumatic heart disease, smoking history, thyroid abnormality, and diabetes mellitus. Fischer’s exact test was performed to compare the difference (in percentage) between AFL patients and AF patients for each of the 11 above-mentioned clinical characteristics. A $P$-value of $<0.05$ was claimed statistically significant. Multivariate logistic regression analysis was performed to obtain odds ratio (OR) and corresponding 95% confidence interval (CI) for the status of AFL for each of the preexisting comorbidities, with adjustment for age and gender. Additional analysis was done including the adjustment for other significantly different pre-existing comorbidities. All analyses were performed using SAS, version 9.1 (SAS Institute, Cary, North Carolina, United States).

Results

During the 4 years of ascertainment, a total of 472 MESA residents were found to have their first ever episode of AFL or AF. These included 76 (16.1%) with AFL and 396 (83.9%) with AF. We excluded 105 subjects who developed both rhythm abnormalities during the incidence period. Important differences were observed in 3 of the 11 variables pre-selected for analysis. Compared with those with AF, patients with AFL were more likely to have had a history of COPD (25% vs. 12%, $P = 0.006$), CHF (28% vs. 17%, $P = 0.05$), and a trend toward more smoking (49% vs.
37%, \( P = 0.06 \)). Patients with AF, on the other hand, were more likely to have had a history of hypertension (63% vs. 47%, \( P = 0.01 \)).

As shown in table 1, there were no differences between the two patient groups with respect to their mean age, gender distribution, or likelihood of having had previous myocardial infarction, thyroid disease, rheumatic heart disease, previous stroke, or diabetes mellitus.

Although there was a non-significant difference in distribution of age (AFL 70.0 vs. AF 72.0, \( P = 0.22 \)) and males (AFL 62% vs. AF 53%, \( P = 0.17 \)) between both groups, we adjusted for both of them, as they could play a confounding role in other associations. After adjusting for age and gender, the associations identified in unadjusted analyses remained. Patients with AFL were twice as likely to have had a history of COPD (OR 2.34, 95% CI: 1.26, 4.32, \( P = 0.007 \)), and CHF (OR 2.00, 95% CI: 1.12, 3.58, \( P = 0.019 \)) compared to those with AF. Also, AFL patients were half as likely to have had a history of hypertension (OR 0.56, 95% CI: 0.34, 0.93, \( P = 0.025 \)) compared to AF patients. Differences in smoking distribution between the groups remained non-significant. There was no significant difference in other clinical characteristics between the two groups. Table 2 summarizes these results.

These statistically significant associations persisted even with COPD, CHF, and hypertension simultaneously included in a multivariate logistic regression model, in addition to age and gender as summarized in table 3.
Discussion

AF and AFL are the two most common sustained cardiac arrhythmias encountered in clinical practice. While it is widely recognized that AF is much more common than AFL, neither the magnitude nor the reasons for this difference are well established. Our investigation evaluated potential differences in the conditions associated with the development of AFL versus AF.

Based on data derived from population-based studies, we have estimated that annually in the United States there are a total of approximately 200,000 incident cases of AFL and 500,000 incident cases of AF. Since AFL and AF frequently coexist, however, we estimate that the number of individuals with their first ever episode of one of these arrhythmias but not the other would be 84,000 incident cases of AFL only and 395,000 incident cases of AF only.

Despite recent therapeutic advances and the fact that both arrhythmias are now potentially ablated, AFL and AF remain independent predictors of major adverse outcomes. A report from MESA showed that even after adjusting for age, sex, and several comorbid conditions, persons diagnosed with either of these atrial tachyarrhythmias in the 1990s have about a 2-fold increased risk of mortality compared to controls in models.

The precise determinants of atrial arrhythmogenesis in humans remain largely unknown. Recent animal studies have provided significant insights into the pathways involved in remodeling, and have indicated the pathophysiological role of remodeling in specific contexts. As in clinical
practice, experimental models have shown that AFL and AF typically occur in the setting of altered structural and electrical substrates.\textsuperscript{14}

Our data show the existence of identifiable differences in the etiologic mechanisms that contribute to the onset of these arrhythmias. Our data suggest that while AFL and AF may share certain common risk factors, these two atrial tachyarrhythmias may also differ in the conditions that predispose their development. We found important differences in 4 of the 11 variables pre-selected for analysis. COPD, CHF, and smoking were all more common among incident cases of AFL, while a history of hypertension was more likely to be present in those with AF. We believe these data suggest that the distinct arrhythmogenic substrates required for the initiation and maintenance of these tachyarrhythmias in humans may be partly determined by selective influences of specific predisposing comorbidities.

The role of CHF in induction of atrial interstitial fibrosis which leads to AF has been documented in multiple animal studies.\textsuperscript{15-17} We postulated that COPD may predispose patients to cardiac arrhythmia either by the direct effects on the right heart through pulmonary hypertension, right ventricular strain, and stretching of the right atrium or as a result of therapeutic modalities used to treat COPD. The effect of metabolic changes (hypoxia and acidosis) could be significant. Multiple studies on human subjects have shown that salbutamol via its beta-2 action significantly enhances atrioventricular nodal conduction and reduces atrioventricular nodal, atrial, and ventricular refractoriness.\textsuperscript{18,19} Epidemiological studies have shown that patients with COPD and asthma treated with oral steroids were at an increased risk of developing AF even after controlling for a few factors of disease severity.\textsuperscript{20} van der Hooft et al\textsuperscript{21} also found a higher
incidence of AF among patients requiring high dose oral steroids regardless of the etiology (rheumatic, allergic, or malignant hematological diseases). One mechanism by which steroids facilitate arrhythmogenesis is via a direct effect on the cell membrane causing potassium efflux from cells.\textsuperscript{22} Theophylline has also been shown to be associated with AF among patients with COPD, interestingly even with normal serum levels.\textsuperscript{23} Theophylline has been shown to decrease the atrioventricular and sinoatrial conduction time significantly while increasing the serum concentration of epinephrine and nor-epinephrine.\textsuperscript{24} Reduction in the atrial refractory period along with dispersed recovery of the excitability secondary to theophylline is presumed to cause multiple reentrant circuits leading to AF. Our study was not designed to address the confounding effects of medications or severity of illness. More basic research and population-based studies are needed to confirm or refute this epidemiological association with AFL but not with AF to have potential clinical or therapeutic implications.

There could be multiple potential physiologic explanations for our findings. In typical AFL for example, it is now clear that its characteristic macro-reentrant circuit is normally limited to the right atrium.\textsuperscript{25} The flutter circuit travels cranially up the interatrial septum and caudally down through the free wall of the right atrium. The area of slow conduction (isthmus), usually located in the inferior portion of the right atrial chamber, is caused by functional rather than constant block. This zone is flanked by areas of anatomical block caused by the inferior vena cava and the tricuspid valve.\textsuperscript{26} It is certainly conceivable, if not likely, that the electro-anatomical substrate required for maintenance of that AFL circuit might be facilitated by the impact of long standing COPD and CHF, as these conditions may all cause increased right atrial pressure, wall stress, myocardial stretching, etc.
The most important breakthrough in understanding the pathophysiology of AF was the description of focal discharges arising from the pulmonary veins near the junction where these veins drain into the left atria, which potentially initiate and perpetuate the cycle.\textsuperscript{1,25} We postulate that the association of AF with systematic hypertension could occur from the relatively greater impact on the left atria of the latter.

We minimized selection bias by identifying all new cases of AFL or AF occurring in the entire population in this region and by using the resources of MESA. Given the intermittent nature of these arrhythmias, frequent lack of symptoms, and obvious technologic requirements, their complete ascertainment in any population would require compulsory, long-term continuous monitoring of all individuals in a given area. By limiting the comparative analysis to subjects with only one of these arrhythmias, we excluded 21% of the incident cases of AF and 58% of the incident cases of AFL. Similar to other population-based studies, our ability to conduct subanalyses of certain subsets was limited. We were unable to account for severity of illness in COPD, CHF, and hypertension. Despite a total enrollment of 577 incident cases, sample size was a limitation. There are several other comorbid conditions and pathophysiologic states that must be evaluated. Also, echocardiographic parameters were not evaluated. Lastly, the population of MESA is predominantly white and rural.

To our knowledge, this study represents the first investigation to compare the prevalence of comorbidities preceding the onset of AF or AFL in a geographically-defined population. Our findings may have potentially important mechanistic and clinical implications and provide a new
potential area for future research into the development and thus prevention of these common arrhythmias.

Acknowledgments

The authors thank Marshfield Clinic Research Foundation for its support through the assistance of Marie Fleisner and Alice Stargardt in the preparation of this manuscript.
References


Author Affiliations

Ravi K. Mareedu, MD
Department of Internal Medicine
Marshfield Clinic and St. Joseph's Hospital
Marshfield, WI 54449, USA

Ihab B. Abdalrahman, MD
Department of Internal Medicine
Marshfield Clinic and St. Joseph's Hospital
Marshfield, WI 54449, USA

Kodlipet C. Dharmashankar, MD
Department of Internal Medicine
Marshfield Clinic and St. Joseph's Hospital
Marshfield, WI 54449, USA

Juan F. Granada, MD
Skirball Center for Cardiovascular Research
Cardiovascular Research Foundation
New York, NY 10022, USA

Po-Huang Chyou, PhD
Biomedical Informatics Research Center
Marshfield Clinic Research Foundation
Marshfield, WI 54449, USA

Param P. Sharma, MD
Department of Cardiology
Marshfield Clinic and St. Joseph's Hospital
Marshfield, WI 54449, USA

Peter N. Smith, MD
Department of Cardiology
Marshfield Clinic and St. Joseph's Hospital
Marshfield, WI 54449, USA

John J. Hayes, MD
Department of Cardiology
Marshfield Clinic and St. Joseph's Hospital
Marshfield, WI 54449, USA

Robert T. Greenlee, PhD
Epidemiology Research Center
Marshfield Clinic Research Foundation
Marshfield, WI 54449, USA
Table 1. Clinical characteristics present at the time of initial diagnosis of atrial flutter (AFL) versus atrial fibrillation (AF) in a general population in the Marshfield Epidemiologic Study Area (MESA)

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>AFL (n=76)</th>
<th>AF (n=396)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>19 (25%)</td>
<td>48 (12%)</td>
<td>0.006</td>
</tr>
<tr>
<td>Hypertension</td>
<td>36 (47%)</td>
<td>250 (63%)</td>
<td>0.01</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>21 (28%)</td>
<td>69 (17%)</td>
<td>0.05</td>
</tr>
<tr>
<td>Smoking history</td>
<td>37 (49%)</td>
<td>146 (37%)</td>
<td>0.06</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>17 (22%)</td>
<td>63 (16%)</td>
<td>0.18</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>12 (16%)</td>
<td>87 (22%)</td>
<td>0.28</td>
</tr>
<tr>
<td>Thyroid disease</td>
<td>9 (12%)</td>
<td>38 (10%)</td>
<td>0.53</td>
</tr>
<tr>
<td>Previous stroke</td>
<td>13 (17%)</td>
<td>62 (16%)</td>
<td>0.73</td>
</tr>
<tr>
<td>Rheumatic heart disease</td>
<td>1 (1%)</td>
<td>5 (1%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Male gender (%)</td>
<td>47 (62%)</td>
<td>210 (53%)</td>
<td>0.17</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>70.0 (SD ± 12.4, 25 to 95)</td>
<td>72.0 (SD ± 12.5, 21 to 94)</td>
<td>0.22</td>
</tr>
</tbody>
</table>

* Based on Fisher’s exact test
<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>OR</th>
<th>CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>2.34</td>
<td>1.26, 4.32</td>
<td>0.007</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.56</td>
<td>0.34, 0.93</td>
<td>0.025</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>2.00</td>
<td>1.12, 3.58</td>
<td>0.019</td>
</tr>
<tr>
<td>Smoking history</td>
<td>1.46</td>
<td>0.86, 2.48</td>
<td>0.163</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>1.67</td>
<td>0.90, 3.10</td>
<td>0.103</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>0.66</td>
<td>0.34, 1.28</td>
<td>0.222</td>
</tr>
<tr>
<td>Thyroid disease</td>
<td>1.46</td>
<td>0.66, 3.21</td>
<td>0.352</td>
</tr>
<tr>
<td>Previous stroke</td>
<td>0.94</td>
<td>0.40, 2.21</td>
<td>0.143</td>
</tr>
<tr>
<td>Rheumatic heart disease</td>
<td>1.12</td>
<td>0.13, 9.91</td>
<td>0.144</td>
</tr>
</tbody>
</table>

* Adjusted for age and gender
Table 3. Odds ratio (OR) and 95% confidence interval (CI) for atrial flutter versus atrial fibrillation according to relevant clinical characteristics

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>OR</th>
<th>CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>1.99</td>
<td>1.04, 3.82</td>
<td>0.038</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.51</td>
<td>0.30, 0.86</td>
<td>0.011</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>1.87</td>
<td>1.00, 3.50</td>
<td>0.050</td>
</tr>
<tr>
<td>Age</td>
<td>0.99</td>
<td>0.97, 1.01</td>
<td>0.265</td>
</tr>
<tr>
<td>Male</td>
<td>1.15</td>
<td>0.66, 1.98</td>
<td>0.624</td>
</tr>
</tbody>
</table>

* Adjusted for age, gender, and other clinical variables included in the same table